CSPC Pharmaceutical Group Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $11.81 billion
- Book Value:
- Revenue TTM:
- $30.94 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $21.14 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
CSPC Pharmaceutical Group Ltd had its IPO on under the ticker symbol CHJTF.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. CSPC Pharmaceutical Group Ltd has a staff strength of 24,746 employees.
Shares of CSPC Pharmaceutical Group Ltd opened at $0.99 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.99 - $1.01, and closed at $0.99.
This is a -7.48% slip from the previous day's closing price.
A total volume of 10,000 shares were traded at the close of the day’s session.
In the last one week, shares of CSPC Pharmaceutical Group Ltd have slipped by -12.39%.
CSPC Pharmaceutical Group Ltd's Key Ratios
CSPC Pharmaceutical Group Ltd has a market cap of $11.81 billion, indicating a price to book ratio of 3.4133 and a price to sales ratio of 0.4467.
In the last 12-months CSPC Pharmaceutical Group Ltd’s revenue was $30.94 billion with a gross profit of $21.14 billion and an EBITDA of $7.48 billion. The EBITDA ratio measures CSPC Pharmaceutical Group Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CSPC Pharmaceutical Group Ltd’s operating margin was 21.85% while its return on assets stood at 11.04% with a return of equity of 21.32%.
In Q3, CSPC Pharmaceutical Group Ltd’s quarterly earnings growth was a positive 28.2% while revenue growth was a positive 3%.
CSPC Pharmaceutical Group Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.06 per share while it has a forward price to earnings multiple of 14.4092 and a PEG multiple of 2.5472. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CSPC Pharmaceutical Group Ltd’s profitability.
CSPC Pharmaceutical Group Ltd stock is trading at a EV to sales ratio of 0.3774 and a EV to EBITDA ratio of 1.6182. Its price to sales ratio in the trailing 12-months stood at 0.4467.
CSPC Pharmaceutical Group Ltd stock pays annual dividends of $0.186 per share, indicating a yield of 2.25% and a payout ratio of 6.68%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
CSPC Pharmaceutical Group Ltd ended 2023 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.
CSPC Pharmaceutical Group Ltd ended 2023 with $0 in deferred long-term liabilities, $0 in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
CSPC Pharmaceutical Group Ltd’s total current assets stands at $0 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2023, CSPC Pharmaceutical Group Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, CSPC Pharmaceutical Group Ltd paid $0.07 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
CSPC Pharmaceutical Group Ltd stock is currently trading at $0.99 per share. It touched a 52-week high of $1.16 and a 52-week low of $1.16. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $1.14 and 200-day moving average was $1.03 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2956.3% of the company’s stock are held by insiders while 3406.2% are held by institutions.
Frequently Asked Questions About CSPC Pharmaceutical Group Ltd
Similar Industry Stocks (Drug Manufacturers-General)
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People’s Republic of China.